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Abstract
Background: This study aimed to determine whether, besides carotid ultrasound (US), a lateral lumbar spine
radiography may also help identify ankylosing spondylitis (AS) patients at high risk of cardiovascular (CV) disease.
Methods: A set of 125 AS patients older than 35 years without a history of CV events, diabetes mellitus, or chronic
kidney disease was recruited. Carotid US and lateral lumbar spine radiography were performed in all of them. The
CV risk was calculated according to the total cholesterol systematic coronary risk evaluation (TC-SCORE) algorithm.
Presence of carotid plaques was defined following the Mannheim Carotid Intima-media Thickness and Plaque
Consensus. Abdominal aortic calcium (AAC) in a plain radiography was defined as calcific densities visible in an area
parallel and anterior to the lumbar spine.
Results: Carotid US showed higher sensitivity than lateral lumbar spine radiography to detect high CV risk in the 54
patients with moderate TC-SCORE (61% versus 38.9%). Using carotid plaques as the gold standard test, a predictive
model that included a TC-SCORE ≥ 5% or the presence of AAC in the lateral lumbar spine radiography in patients
with both moderate and low CV risk (< 5%) according to the TC-SCORE yielded a sensitivity of 50.9% with a specificity
of 95.7% to identify high/very high CV-risk AS patients. A positive correlation between AAC and carotid plaques was
observed (r2 = 0.49, p < 0.001).
Conclusions: A lateral lumbar spine radiography is a useful tool to identify patients with AS at high risk of CV disease.
Keywords: Ankylosing spondylitis, Cardiovascular disease, Abdominal aortic calcification, Lumbar lateral spine radiography,
Carotid ultrasonography
Background
As occurs with other chronic inflammatory conditions, anky-
losing spondylitis (AS) is associated with a process of acceler-
ated atherosclerosis [1, 2] which leads to increased rates of
subclinical atherosclerosis [3] and cardiovascular (CV) events
[4]. A recent meta-analysis of seven longitudinal studies re-
ported an increased frequency of myocardial infarction (odds
ratio (OR) 1.60, 95% confidence interval (CI) 1.32–1.93) and
stroke (OR 1.50, 95% CI 1.39–1.62) in AS patients when
compared to the general population [4]. In a
population-based study which included 21,473 AS patients
and 86,606 controls matched for age, sex, and location of
residence, Haroon et al. [5] found a 36% higher risk of vascu-
lar mortality in AS.
Primary prevention strategies designed to avoid
atherosclerosis-related CV events in the general popula-
tion are based on the identification of individuals at high
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CV risk who can benefit from appropriate prevention
measures [6]. In this regard, statin use has proved to be
very effective, being able to reduce overall mortality by
15% [7]. The benefit may be even greater in AS patients
according to a recent study which found a 37% lower
risk of all-cause mortality associated with statin initiation [8].
The 2016 “European Guidelines on CV disease pre-
vention in clinical practice” recommended using the
total cholesterol systematic coronary risk evaluation
(TC-SCORE) to stratify the CV risk and to identify indi-
viduals at high CV risk who were candidates for treat-
ment [6]. The TC-SCORE predicts the individual’s
absolute risk for fatal CV events considering age, sex,
total cholesterol levels, smoking, and blood pressure,
stratifying the CV risk into low (< 1%), moderate (≥ 1
and < 5%), high (≥ 5 and < 10%), and very high (≥ 10%).
Unfortunately, predictive models designed for the gen-
eral population do not consider the inflammatory
process as a proatherogenic factor, leading to an under-
estimation of the CV risk when used in inflammatory
diseases like AS. In this regard, a recent study disclosed
in AS patients a 10-year cumulative incidence of CV
events three times higher than that predicted based on
the Framingham Risk Score (FRS) [9].
In an attempt to improve the TC-SCORE predictions,
the 2016 European Society of Cardiology (ESC) guide-
lines proposed the use of different imaging techniques
to identify high-CV risk individuals with subclinical
atherosclerosis [6]. Carotid ultrasonography (US) and
multidetector coronary tomography (MDCT) allow one
to detect, respectively, carotid plaques and coronary
calcifications, which are considered independent pre-
dictors of CV events capable of providing additional
value to the FRS when estimating CV risk [10, 11]. Ac-
cording to the 2016 ESC guidelines, the presence of
both surrogate markers of atherosclerosis automatically
implies a very high CV risk [6]. Our group has recently
demonstrated that carotid US and MDCT are very use-
ful to redefine the CV risk in AS: up to 63% and 30% of
our AS patients with moderate CV risk according to
the SCORE risk charts had carotid plaques and coron-
ary calcifications, respectively [12]. However, the re-
stricted availability of MDCT in the daily clinical
practice and the considerable amount of radiation asso-
ciated with the use of this technique may be limitations
for to its generalized use.
Abdominal aortic calcium (AAC) constitutes another
surrogate marker of atherosclerosis easily detectable in a
lateral lumbar spine radiography [13]. Unlike MDTC, it
is available in most AS patients. Aortic calcification has
been demonstrated to represent true intimal atheroscler-
osis in postmortem studies [14], correlating with the de-
gree of atherosclerosis in the coronary arterial beds [15].
As occurs with carotid plaques and coronary
calcification, AAC deposits constitute an independent
predictor of subsequent vascular morbidity and mortality
capable of improving the risk prediction based on the
FRS [16].
Taking all these considerations into account, the pur-
pose of the present study is to determine whether, be-
sides carotid US, the presence of ACC deposits detected
by plain lumbar spine radiographs is able to improve the
identification of those AS patients with high/very high




In this cross-sectional study, a set of 125 consecutive AS
patients seen over a 5-year period at Hospital Universi-
tario Marqués de Valdecilla and Hospital de Laredo (Can-
tabria, northern Spain) who fulfilled definitions for AS
according to the 1984 modified New York criteria [17]
were recruited. Patients with a history of CV events (is-
chemic heart disease, cerebrovascular accident, peripheral
arterial disease, or heart failure) were excluded. This was
also the case for those with type 2 diabetes mellitus or
with two fasting plasma glucose levels on different days at
the time of disease diagnosis or over the extended
follow-up > 125 mg/dl as well as those with chronic kid-
ney disease (glomerular filtration rate < 60 ml/min/
1.73 m2) because they are considered as having high or
very high CV risk according to current guidelines.
Two clinical indexes of disease activity (Bath Ankylos-
ing Spondylitis Disease Activity Index (BASDAI) and
Ankylosing Spondylitis Disease Activity Score (ASDAS)),
a functional status index (Bath Ankylosing Spondylitis
Functional Index (BASFI)), a metrologic index (Bath An-
kylosing Spondylitis Metrology Index (BASMI)), and an
enthesitis index (Maastricht Ankylosing Spondylitis
Enthesitis Score (MASES)) were evaluated in all patients
at the time of the carotid US assessment [18–22].
Information on history of hip involvement, synovitis,
enthesitis, extra-articular manifestations (anterior uve-
itis, psoriasis, and inflammatory bowel disease), syndes-
mophytes, and HLA-B27 status was also assessed. This
was also the case for data on family history of early CV
events in first-degree relatives, waist circumference, body
mass index, blood pressure at the time of study, and his-
tory of traditional CV risk factors (smoking, hyperten-
sion, dyslipidemia, and obesity).
Data on C-reactive protein (CRP) and the erythrocyte
sedimentation rate (ESR) at the time of recruitment and
at disease diagnosis, identification of patients with CRP
serum levels higher than 3 mg/L at the time of diagno-
sis, and total cholesterol, HDL-cholesterol, LDL-choles-
terol, and triglycerides at the time of the study were also
assessed. Information on therapy including treatment
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with anti-tumor necrosis factor (anti-TNF) alpha agents
from the disease diagnosis was also reviewed.
The TC-SCORE system estimates the 10-year risk of a
first fatal atherosclerotic event, whether heart attack,
stroke, or other occlusive arterial disease, including sud-
den cardiac death. Risk estimates have been produced as
charts for high and low-risk regions in Europe [6]. Spain
was included in the low-risk region of Europe. The risk
factors incorporated in the TC-SCORE are those previ-
ously described: age, gender, smoking, total cholesterol
levels, and systolic blood pressure. Subjects with
TC-SCORE < 1% are included in the category of low risk.
Those with a TC-SCORE ≥ 1% and < 5% are in the cat-
egory of moderate risk. When the chart TC-SCORE re-
sult is ≥ 5% and < 10% they are classified as having high
risk. Finally, those patients with TC-SCORE results ≥
10% are included in the category of very high CV risk.
The earliest age at which the CV risk scores should be
used in the general population has not been rigorously
established. Both European [6] and North American [23]
guidelines recommend their application in individuals
over 40 years old. However, this cutoff point is not uni-
form and varies across the different CV risk scores:
30 years old for the FRS [24], 40 years old for the
TC-SCORE [6], and 45 years old for the Reynolds Risk
Score [25], which can only be applied from this age on-
ward. In Spain, the Framingham-based REGICOR
adapted function, a CV risk function validated in the
Spanish population [26], established its use at an inter-
mediate point of 35 years old. Since patients with AS
have early accelerated atherosclerosis, and we observed
carotid plaques in patients under 40 years old, we in-
cluded in the analysis all patients who were age 35 years
and older.
Carotid US examination
A set of 125 AS patients underwent carotid US examin-
ation to detect focal plaques in the extracranial carotid
tree. According to the Mannheim Carotid Intima-media
Thickness and Plaque Consensus, a carotid plaque was
defined as a focal protrusion in the lumen at least cIMT
> 1.5 mm, protrusion at least 50% greater than the sur-
rounding cIMT, or arterial lumen encroaching > 0.5 mm
[27]. Carotid US was performed using a commercially
available scanner (Mylab 70; Esaote, Genoa, Italy)
equipped with a 7–12 MHz linear transducer and the
automated software-guided radiofrequency technique
Quality Intima Media Thickness in real time (QIMT;
Esaote, Maastricht, Holland). Patients with carotid pla-
ques were considered as having very high CV risk.
Evaluation of abdominal aortic calcium deposits
The lateral lumbar spine radiography was performed in
the standing position and all X-ray scans were evaluated
by an independent reader blinded to the participant’s
clinical status. We assessed the presence of calcific de-
posits at each vertebral segment from the first to fourth
lumbar vertebrae, both in the posterior and anterior
walls of the aorta (Fig. 1). Calcific deposits were
regarded as present if densities were visible in an area
parallel to the lumbar spine and anterior to the lower
part of the spine. Aortic densities at the upper part of
the lumbar spine (L1–L2 region) often overlapped the
vertebrae as the abdominal aorta in the L1–L2 region is
often lateral to the spine. Densities overlapping the ver-
tebrae were deemed present only if they extended from
or formed a clear pattern with those of the lower part of
the aorta. Since calcific deposits tend to occur first in
the lower aorta [28, 29], calcific deposits at the upper
levels were almost always accompanied by extensive cal-
cifications in the lower part of the aorta. Other calcific
deposits visible in lumbar films, such as intestinal calcifi-
cations and calcified costal cartilages, were clearly distin-
guishable from aortic calcifications (Fig. 1).
The reproducibility of the evaluation of AAC deposits
was also evaluated in 20 patients by two investigators (JR-G
and AC). The correlation coefficient for AAC was 0.96.
The subject’s written consent was obtained for all of
the cases. The study was approved by the local ethical
committee.
Statistical analysis
Categorical variables were described as percentages and
quantitative variables as mean ± standard deviation (SD)
or median (interquartile range (IQR)).
Correlation between the presence of carotid plaques
and lumbar aortic calcification was analyzed using the
Pearson correlation. For each CV risk model, sensitivity,
specificity, percentage of correctly classified patients,
and area under the receiver operating characteristic
(ROC) curve (with 95% CI) were estimated.
Results
Characteristics of AS patients
The main features of the 125 AS patients included in
the study are summarized in Table 1.
Men outnumbered women (n = 78; 62.4%) and the
mean ± SD age at the time of the study was 48.3 ±
9.6 years. HLA-B27 was positive in 92 (74.8%) patients,
and syndesmophytes were present in 51 (41.5%) patients.
Thirty-eight (30.4%) patients had extra-articular mani-
festations: uveitis, psoriasis, and inflammatory bowel dis-
ease were present in 17.6%, 9.6%, and 8% of patients,
respectively. The mean ± SD values of the BASDAI and
ASDAS were 3.7 ± 2.0 and 2.4 ± 0.9. Seventy-two (57.6%)
patients were found to have CRP > 3 mg/L at the time of
disease diagnosis. TNF inhibitors were used in 39.8% of
cases. Regarding findings of subclinical atherosclerosis,
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carotid plaques and AAC deposits were found in 55
(44.0%) and 28 (22.4%) patients, respectively. Other
characteristics of this series of patients with AS are pre-
sented in Table 1.
TC-SCORE risk groups and severe atherosclerotic disease
using carotid US and lateral spine radiography
The CV risk was calculated using the TC-SCORE. Based
on this algorithm, patients were classified into four dif-
ferent CV risk categories: low, moderate, high, and very
high. Then, the frequency of carotid plaques in each cat-
egory was calculated to assess the ability of the
TC-SCORE to correctly classify patients as having high/
very high CV risk (Table 2). We also analyzed the preva-
lence of AAC in the lateral spine radiography in each
group of risk (Table 2). Following this approach, 33 of
54 (61.1%) patients classified as having moderate CV ac-
cording to the TC-SCORE had plaques when the carotid
US was performed, whereas 21 of 54 (38.9%) patients
with moderate CV risk according to the TC-SCORE also
had AAC in the lateral lumbar spine radiography. More-
over, 23.4% and 4.7% of AS patients who fulfilled the
category of low CV risk according to the TC-SCORE
had carotid plaques and AAC, respectively (Table 2).
Correlation between AAC and carotid US in AS patients
The validity of lateral lumbar spine radiography to iden-
tify AS patients at high CV risk was assessed by analyz-
ing the correlation between AAC and carotid plaques
(Table 3). We observed that 25 of 28 (89.3%) patients
with AAC deposits also had plaques in the carotid US
assessment. Regarding patients without AAC deposits in
the lateral lumbar spine radiography, 69.1% of them did
not have carotid plaques either (Table 3). We observed a
positive correlation between AAC and carotid plaques
(r2 = 0.49, p < 0.001).
Model to establish the presence of high/very high CV risk
in patients with AS
Since many patients categorized as having low or moder-
ate CV risk when the TC-SCORE was applied had subclin-
ical atherosclerosis, we set up a predictive model to
identify AS patients with high/very high CV risk (Table 4).
In this regard, according to the ESC 2016 guidelines, we
Fig. 1 Abdominal aortic calcifications and calcified costal cartilages. Abdominal aortic calcifications seen as calcium deposits localized in area
parallel to lumbar spine and anterior to lower part of spine (long arrow). Calcified costal cartilages have a typical pattern distinguishable from
aortic calcifications (arrowhead)
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classified patients as having high/very high CV risk if they
had carotid plaques in the carotid US [6]. Following this
approach, 55 of 125 patients fulfilled definitions of high/
very high CV risk. However, only 7 (12.7%) of them were
detected using the TC-SCORE, without the inclusion in
the model of results of imaging techniques (model 1). The
detection of aortic atherosclerosis by lateral lumbar spine
radiography yielded a high specificity (95.7%) with low
sensitivity (45.5%) to identify AS patients with very high
CV risk (model 2). A predictive model that included a
TC-SCORE ≥ 5% or the presence of AAC in lateral lumbar
spine radiography in patients with moderate CV risk ac-
cording to the SCORE (≥ 1% and < 5%) (model 3) showed
the same results as those found in model 2. A higher sen-
sitivity (50.9%) with the same specificity (95.7%) was
achieved when the predictive model included TC-
SCORE ≥ 5% or the presence of AAC in the lateral lumbar
spine radiography in patients with both moderate and low
CV risk according to the TC-SCORE (< 5%) (model 4).
Discussion
To the best of our knowledge this is the first study that
aimed to assess the ability of the lateral lumbar spine
radiography, a diagnostic tool widely available in AS
Table 1 Features of 125 ankylosing spondylitis (AS) patients
Variable AS (n = 125)
Men/women, n 78/47
Age at time of study (years), mean ± SD 48.3 ± 9.6
Age at time of diagnosis (years), mean ± SD 39.5 ± 9.6
HLA-B27 positive, n (%) 92 (74.8)
Syndesmophytes, n (%) 51 (41.5)
History of synovitis, n (%) 35 (28.0)
History of enthesitis, n (%) 45 (36.0)
Extra-articular manifestations, n (%) 38 (30.4)
Psoriasis 12 (9.6)
Inflammatory bowel disease 10 (8.0)
Uveitis 22 (17.6)
Therapy with TNF inhibitors, n (%) 49 (39.8)
ASDAS, mean ± SD 2.4 ± 0.9
BASFI, mean ± SD 3.9 ± 2.5
BASMI, mean ± SD 3.2 ± 1.7
MASES, median (IQR) 1 (0.0–4.0)
BASDAI, mean ± SD 3.7 ± 2.0
CRP (mg/l), median (IQR)
At time of study 5.2 ± 6.7
At time of disease diagnosis 10.8 ± 19.0
CRP > 3 mg/L at time of disease diagnosis, n (%) 72 (57.6)
ESR (mm/1st hour), median (IQR)
At time of study 12.4 ± 13.4
At time of disease diagnosis 16.1 ± 15.9
History of classic cardiovascular risk factors, n (%)





Blood pressure (mmHg), mean ± SD
Systolic 130.6 ± 15.3
Diastolic 79.5 ± 9.7
Cholesterol and triglycerides (mg/dl), mean ± SD
Total cholesterol 200.7 ± 34.5
HDL cholesterol 55.6 ± 14.8
LDL cholesterol 124.6 ± 31.7
Triglycerides 97.3 ± 49.4
Carotid plaques, n (%) 55 (44.0)
Aortic calcification, n (%) 28 (22.4)
TC-SCORE ≥ 5, n (%) 7 (5.6)
Main epidemiologic, clinical, radiographic, and ultrasonography features of a
series of 125 AS patients older than 35 years of age without history of
cardiovascular events, diabetes mellitus, or chronic kidney disease
ASDAS Ankylosing Spondylitis Disease Activity Score, BASDAI Bath Ankylosing
Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional
Index, BASMI Bath Ankylosing Spondylitis Metrology Index, CRP C-reactive protein,
ESR erythrocyte sedimentation rate, HDL high-density lipoprotein, IQR interquartile
range, LDL low-density lipoprotein, MASES Maastricht Ankylosing Spondylitis
Enthesitis Score, SD standard deviation TC-SCORE total cholesterol systematic
coronary risk evaluation, TNF tumor necrosis factor
Table 2 Prevalence of carotid plaques and abdominal aortic
calcium in the different groups of cardiovascular risk
TC-SCORE Carotid ultrasonography Lateral lumbar X-ray
Carotid plaques
(n = 55, 44%)
AAC deposits
(n = 28, 22.4%)
Low (< 1%) n = 64 15/64 (23.4%) 3/64 (4.7%)
Moderate
(≥ 1% and < 5%)
n = 54 33/54 (61.1%) 21/54 (38.9%)
High (≥ 5% and
< 10%)
n = 7 7/7 (100%) 4/7 (57.1%)
Very high (≥ 10%) n = 0 0 (0%) 0 (0%)
Presence of carotid plaques and AAC deposits in 125 ankylosing spondylitis
patients older than 35 years of age without cardiovascular events, diabetes
mellitus, or chronic kidney disease, classified according to their
cardiovascular risk
AAC abdominal aortic calcium, TC-SCORE total cholesterol systematic coronary
risk evaluation
Table 3 Correlation between abdominal aortic calcium (AAC)
deposits and carotid plaques
Lateral lumbar X-ray Carotid ultrasonography
Presence of carotid
plaques
(n = 55/125, 44%)
Absence of carotid
plaques










30/97 (30.9%) 67/97 (69.1%)
Correlation between the presence of AAC deposits and the presence of carotid
plaques in 125 patients with ankylosing spondylitis older than 35 years of age
without cardiovascular events, chronic kidney disease, or diabetes mellitus
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patients, to improve the CV risk stratification in patients
with AS. We observed that the presence of AAC de-
posits detected by a lateral lumbar spine radiography al-
lows one to identify individuals with AS at high risk of
CV disease. In this regard, in the present series of 125
AS patients without CV events, chronic kidney disease,
or diabetes mellitus, 21 of 54 (38.9%) patients with mod-
erate TC-SCORE and 3 of 64 (4.7%) patients with low
TC-SCORE showed AAC in the lateral lumbar spine
radiography.
The presence of AAC in a plain radiography has been
reported to be associated with an increased risk of CV
events, CV mortality [13], and congestive heart failure
[30] in the Framingham cohort. Overall, AAC adds to
the prediction for intermittent claudication (IC), ische-
mic stroke (IS), and coronary heart disease over and
above traditional CV risk factors in patients with low
and intermediate risk [16]. AAC deposits also demon-
strated to be a predictor of incident stroke in the Rotter-
dam study, even stronger than carotid plaques [31]. Both
the Rotterdam and the Framingham studies used a
quantitative scale to grade the severity of the aortic cal-
cium deposits. It is worth noting that, even though the
increase of CV risk was found to be proportional to the
extent of the calcifications, AAC demonstrated to be a
predictor of CV events and mortality also in cases of re-
duced calcifications. In keeping with these findings, in a
Netherlands population Witteman et al. [32] found a
strong independent association between CV deaths and
aortic calcifications of any size, regardless of the extent
of the calcific deposits. A postmortem study that ana-
lyzed the accuracy of the radiologic AAC for the
diagnosis of true aortic atherosclerosis confirmed that
even the smaller densities indicated the presence of ad-
vanced atheromatous plaques, which were almost invari-
ably ulcerated [14]. Witteman et al. [32] also disclosed a
high predictive role of AAC for CV death in young indi-
viduals, with a six-fold increased risk in men aged
45 years independently of the major CV risk factors, and
no excess risk at age 75 years. These findings are par-
ticularly relevant in AS patients since the disease typic-
ally starts before the age of 45 years and the TC-SCORE
tends to underestimate the CV risk, especially in this age
group in which practically all patients are classified as
having low or moderate CV risk. Indeed, the mean age
in our series was 48 years and 118 of the 125 (94%) AS
patients were found to have a low or moderate
TC-SCORE.
The 2014 ESC guidelines on the diagnosis and treat-
ment of aortic diseases [33] recommended adopting gen-
eral preventive measures to control risk factors in the
presence of aortic atherosclerosis. Treatment with statins
led to regression of thoracic aortic and retardation of ab-
dominal aortic atheroma burden assessed by magnetic
resonance imaging [34], as well as reduction of the in-
flammation assessed by PET [35]. In a retrospective
study of 519 patients with severe aortic plaque seen on
transesophageal echocardiography, only statin treatment
was associated with a 70% lower risk of events [36]. A
correlation between AAC and atherosclerotic findings in
the carotid and coronary arterial beds has previously
been reported [15, 37]. This finding constitutes an add-
itional argument to support statin use in AS patients
with AAC. The presence of carotid plaques, considered
a surrogate marker of subclinical atherosclerosis in the
2016 ESC guidelines, automatically implies a very high
CV risk with the consequent indication of statin use.
Taking into account these considerations, we can con-
clude that almost 50% of AS included in the categories
of low and moderate CV risk according to the TC-
SCORE risk algorithm would benefit from additional pri-
mary prevention measures, with special emphasis on the
use of statins, if a plain lateral lumbar spine radiography
is performed. This is a crucial aspect considering that
statins have been shown to decrease mortality by 37% in
AS, a figure double that observed in the general popula-
tion [8].
The major limitation of our study was the absence of
prospective follow-up data for the studied patients. Be-
cause of this, we dealt with a surrogate outcome based
on extrapolation of the data that might not be applicable
to AS.
In an attempt to elucidate the best strategy to identify
AS patients at high CV risk, we assessed the ability of
lateral lumbar spine radiography to detect severe find-
ings of subclinical atherosclerosis. A predictive model
Table 4 Diagnostic models designed to identify ankylosing
spondylitis patients with very high cardiovascular risk using


















45.5 95.7 73.6 0.71
(0.64–0.78)
Model 3. TC-SCORE≥
5% or TC-SCORE≥ 1%
and< 5% plus lateral
lumbar spine radiography
(presence of AAC)
45.5 95.7 73.6 0.71
(0.64–0.78)
Model 4. TC-SCORE≥ 5%




50.9 95.7 76.0 0.73
(0.66–0.80)
AAC abdominal aortic calcium, CI confidence interval, ROC receiver operating
characteristic, TC-SCORE total cholesterol systematic coronary risk evaluation
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that included a TC-SCORE ≥ 5% or the presence of AAC
in lateral lumbar spine radiography in patients with a
low or moderate TC-SCORE (TC-SCORE < 5%) allowed
us to detect half of the AS patients with high/very high
CV-risk, also demonstrating a high degree of specificity
(95.7%).
Conclusions
When carotid US is not available, plain lateral lumbar
spine radiography can be an easy and affordable tool to
identify AS patients at high CV risk.
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